Related Experiment Videos
The Vena Tech LP Permanent Caval Filter: Effectiveness and Safety in the Clinical Setting in Three Chinese Medical
Fuxian Zhang1, Dajun Li2, Jianlong Liu3
1Department of Vascular Surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
Insights
Vena Tech LP caval filters demonstrated effectiveness and safety for preventing pulmonary embolism (PE) in Chinese patients. The study showed good long-term patency and stability in both the inferior vena cava (IVC) and superior vena cava (SVC).
Area of Science:
- Vascular Surgery
- Interventional Radiology
- Cardiology
Background:
- Pulmonary embolism (PE) remains a significant cause of morbidity and mortality.
- Inferior vena cava (IVC) and superior vena cava (SVC) filters are used to prevent PE in high-risk patients.
- Limited data exists on the long-term outcomes of specific caval filter devices in the Chinese population.
Purpose of the Study:
- To evaluate the effectiveness, safety, and patient outcomes of Vena Tech LP caval filter placement.
- To assess the long-term patency and stability of the Vena Tech LP filter in both IVC and SVC.
- To analyze complications and clinical adverse events associated with the Vena Tech LP filter in a Chinese cohort.
Main Methods:
- Retrospective analysis of 1,200 patients who received Vena Tech LP caval filters between January 2002 and January 2013.
- Data collection included patient demographics, DVT and PE status, filter placement details (femoral/jugular access, IVC/SVC location), complications, and follow-up.
- Follow-up was conducted for an average of 6 years, assessing filter patency, recurrent PE, and mortality.
Main Results:
- Filter placement was 100% successful via femoral or jugular veins for both IVC (1,138 patients) and SVC (62 patients) locations.
- The 30-day morbidity rate was 2% and mortality was 0.5%.
- Long-term follow-up (80% of patients) showed a 90% vena cava patency rate at 5 years, no recurrent PE, and a 2.4% long-term mortality rate.
Conclusions:
- Vena Tech LP caval filter placement is an effective and safe procedure for preventing PE in Chinese patients.
- The Vena Tech LP filter demonstrates good long-term stability and a high patency rate in both IVC and SVC.
- The study supports the use of Vena Tech LP filters for PE prevention with favorable patient outcomes.
Objective:
The effectiveness, safety, and patient outcomes after Vena Tech LP caval filter placement were evaluated retrospectively in China.
Methods And Results:
From January 2002 to January 2013, 1,200 patients received Tech LP caval filters to prevent PE at three Beijing University medical centers. The patients' general condition, reasons for DVT formation, filter placement method, indication for filter placement, complications, safety of the filter, treatment post-filter, and follow-up were recorded. The patients' mean age was 65 (range, 19-87) years, and 840 were males. Before filter placement, all had ultrasonic-diagnosed DVT, 84% (1008/1200) were assessed for PE, and 73% (736/1008) had PE. Filters were placed via the femoral or jugular vein, with 62 placements at the SVC and 1,138 at the IVC. Filter placement via various venous access routes was 100% successful. Anticoagulation therapy was continued in 88% patients (n=1056) for ≥6 months after filter placement. Follow-up was accomplished in 80% (n=960) of patients for an average of 6 years (range, 3 months to 10 years). The patency rate of the vena cava was 90% at 5 years. The morbidity was 2% and the mortality was 0.5% during 30 days post-filter placement. After 30 days, the mortality rate was 2.4%, no PE reoccurred, and there were no other clinical adverse events.
Conclusion:
Vena Tech LP caval filter placement was effective and safe, with demonstrated stability and a good long-term patency rate at the IVC and SVC in China.